In last trading session, Relmada Therapeutics Inc (NASDAQ:RLMD) saw 0.74 million shares changing hands with its beta currently measuring 0.61. Company’s recent per share price level of $0.29 trading at -$0.02 or -6.05% at ring of the bell on the day assigns it a market valuation of $8.90M. That closing price of RLMD’s stock is at a discount of -2389.66% from its 52-week high price of $7.22 and is indicating a premium of 3.45% from its 52-week low price of $0.28.
For Relmada Therapeutics Inc (RLMD), analysts’ consensus is at an average recommendation of Sell while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Relmada Therapeutics Inc (NASDAQ:RLMD) trade information
Upright in the red during last session for losing -6.05%, in the last five days RLMD remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $0.29 price level, adding 19.31% to its value on the day. Relmada Therapeutics Inc’s shares saw a change of -43.27% in year-to-date performance and have moved -10.23% in past 5-day. Relmada Therapeutics Inc (NASDAQ:RLMD) showed a performance of -24.34% in past 30-days.
Wall Street analysts have assigned a consensus price target of 7 to the stock, which implies a rise of 95.86% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 8. It follows that stock’s current price would drop -589.66% in reaching the projected high whereas dropping to the targeted low would mean a loss of -589.66% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -2.94% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 16.46% while estimates for its earnings growth in next 5 years are of 25.49%.
Relmada Therapeutics Inc (NASDAQ:RLMD)’s Major holders
DEEP TRACK CAPITAL, LP is the top institutional holder at RLMD for having 1.23 million shares of worth $3.7 million. And as of 2024-06-30, it was holding 16.3686 of the company’s outstanding shares.
The second largest institutional holder is VESTAL POINT CAPITAL, LP, which was holding about 1.2 million shares on 2024-06-30. The number of shares represents firm’s hold over 15.9076 of outstanding shares, having a total worth of $3.6 million.
On the other hand, Vanguard Total Stock Market Index Fund and Franklin Strategic Series-Franklin Biotechnology Discove are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 851.92 shares of worth $0.25 million or 8.61% of the total outstanding shares. The later fund manager was in possession of 456.4 shares on Oct 31, 2024 , making its stake of worth around $0.13 million in the company or a holder of 4.61% of company’s stock.
